Ovid Therapeutics (OVID) Capital Expenditures (2016 - 2024)
Ovid Therapeutics (OVID) posted Capital Expenditures of -$26000.0 for Q4 2024, down 126.8% on a QoQ basis from $97000.0 in Q2 2024, and down 137.14% year-over-year from $70000.0 in Q1 2024.
Ovid Therapeutics (OVID) Capital Expenditures (2016 - 2024) Analysis & Trends
Ovid Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at -$26000.0 for Q4 2024.
- Quarterly Capital Expenditures fell 137.14% year-over-year to -$26000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$26000.0 (down 113.98% YoY) and the FY2024 annual result came in at $90000.0, down 7.22% from the prior year.
- Capital Expenditures was -$26000.0 for Q4 2024 at Ovid Therapeutics, down from $97000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.1 million in Q2 2022 and bottomed at -$26000.0 in Q4 2024.
- A 5-year average of $103268.2 and a median of $23759.0 in 2020 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures soared 9067.26% — and 2024, when it plunged 137.14%.
- Ovid Therapeutics' Capital Expenditures stood at $178083.0 in 2020, then slipped by 9.05% to $161958.0 in 2021, then decreased by 25.94% to $119939.0 in 2022, then tumbled by 41.64% to $70000.0 in 2023, then plunged by 137.14% to -$26000.0 in 2024.
- Business Quant data shows OVID's Capital Expenditures at -$26000.0 in Q4 2024, $97000.0 in Q2 2024, and $19000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -26,000.00 |
| Dec 31, 2024 | -26,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Dec 31, 2022 | 119,939.00 |
| Dec 31, 2022 | 119,939.00 |
| Sep 30, 2022 | 18,600.00 |
| Sep 30, 2022 | 18,600.00 |
| Jun 30, 2022 | 1.06 Mn |
| Jun 30, 2022 | 1.06 Mn |